流式细胞术在评估非霍奇金淋巴瘤骨髓受累中的临床价值

[Clinical value of flow cytometry in assessing bone marrow involvement of non-Hodgkin's lymphoma].

作者信息

Song Weiwei, Xie Yan, Deng Lijuan, Shi Yunfei, Li Xianghong, Zheng Wen, Wang Xiaopei, Lin Ningjing, Tu Meifeng, Ying Zhitao, Ping Lingyan, Liu Weiping, Zhang Chen, Ding Ning, Song Yuqin, Zhu Jun

机构信息

Peking University Cancer Hospital and Institute, Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, China.

Peking University Cancer Hospital and Institute, Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, China. Email:

出版信息

Zhonghua Yi Xue Za Zhi. 2014 Oct 21;94(38):2996-3000.

PMID:25547702

Abstract

OBJECTIVE

To evaluate the value of flow cytometry (FCM) in the diagnosis of bone marrow involvement in patients with non-Hodgkin's lymphoma (NHL).

METHODS

The cytomorphology, biopsy and FCM tests were performed concurrently on bone marrow samples from 206 patients who were consecutively diagnosed as NHL from March 2013 to August 2013 at Peking University Cancer Hospital. The results were analyzed and compared.

RESULTS

Totally bone marrow involvement occurred in 25.7% (53/206) patients. The detection positivity of bone marrow involvement by cytomorphology, biopsy and flow cytometry were 6/14, 6/14 and 9/14 respectively in 14 T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia (T-LBL/ALL) patients; 9.2% (14/152) , 19.1% (29/152) and 23.7% (36/152) respectively in 152 mature B-cell NHL patients; 0 (0/40) , 15.0% (6/40) and 2.5% (1/40) in 40 cases of mature T/NK-cell NHL. The overall rate of concordance of biopsy and flow cytometry was 88.3%.

CONCLUSIONS

FCM has a high sensitivity in detecting bone marrow involvement in NHL patients, especially those with T-LBL/ALL and B-cell NHL. And a combination of morphology, biopsy and FCM may improve the sensitivity and accuracy in the detection of bone marrow involvement in NHL patients.

摘要

目的

评估流式细胞术（FCM）在非霍奇金淋巴瘤（NHL）患者骨髓受累诊断中的价值。

方法

对2013年3月至2013年8月在北京大学肿瘤医院连续诊断为NHL的206例患者的骨髓样本同时进行细胞形态学、活检及FCM检测。对结果进行分析和比较。

结果

25.7%（53/206）的患者存在骨髓受累。在14例T细胞淋巴母细胞淋巴瘤和T细胞急性淋巴细胞白血病（T-LBL/ALL）患者中，细胞形态学、活检及流式细胞术检测骨髓受累的阳性率分别为6/14、6/14和9/14；在152例成熟B细胞NHL患者中，分别为9.2%（14/152）、19.1%（29/152）和23.7%（36/152）；在40例成熟T/NK细胞NHL患者中，分别为0（0/40）、15.0%（6/40）和2.5%（1/40）。活检与流式细胞术的总体符合率为88.3%。